Last Updated: June 25, 2026

CLINICAL TRIALS PROFILE FOR APRACLONIDINE HYDROCHLORIDE

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for APRACLONIDINE HYDROCHLORIDE

Subscribe to access the full database, or Start Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00567411 ↗	Comparison of the Alpha-2 Agonists for Prevention of Intraocular Pressure Elevation After Selective Laser Trabeculoplasty	Unknown status	Walter Reed Army Medical Center	N/A	2006-08-01	The purpose of the study is to compare the safety and efficacy of two drops used to lower eye pressure when given prior to a glaucoma laser procedure.
NCT05045248 ↗	Efficacy of Apraclonidine Eye Drops in the Treatment of Ptosis Secondary to Myasthenia Gravis	Completed	American University of Beirut Medical Center	Phase 2	2020-06-01	This study is aimed at assessing the efficacy of Apraclonidine eye drops in the treatment of ptosis secondary to myasthenia gravis.
NCT05167760 ↗	Efficacy of Topical Apraclonidine for the Treatment of Ocular Synkinesis	Not yet recruiting	University of Alabama at Birmingham	Phase 4	2022-02-01	The purpose of this study is to determine efficacy of apraclonidine for patients with ocular synkinesis, who are seen in the UAB Facial Nerve Clinic.
NCT06444529 ↗	A Double-Masked Comparison of FID 123320 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness	COMPLETED	Alcon Research	PHASE3	2024-08-21	The purpose of this study is to assess the safety and efficacy of Apraclonidine Hydrochloride Ophthalmic Solution 0.125% when compared to Vehicle, in relieving redness of the eye due to minor eye irritations. This study will be conducted in the United States.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for APRACLONIDINE HYDROCHLORIDE

Condition Name

Chart
Table

Condition Name for APRACLONIDINE HYDROCHLORIDE
Intervention	Trials
Ocular Hypertension	1
Ocular Myasthenia Gravis	1
Ocular Redness	1
Synkinesis	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for APRACLONIDINE HYDROCHLORIDE
Intervention	Trials
Facial Nerve Diseases	1
Bell Palsy	1
Myasthenia Gravis	1
Muscle Weakness	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for APRACLONIDINE HYDROCHLORIDE

Trials by Country

Map
Table

Trials by Country for APRACLONIDINE HYDROCHLORIDE
Location	Trials
United States	6
Lebanon	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for APRACLONIDINE HYDROCHLORIDE
Location	Trials
Virginia	1
Pennsylvania	1
North Carolina	1
California	1
Alabama	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for APRACLONIDINE HYDROCHLORIDE

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for APRACLONIDINE HYDROCHLORIDE
Clinical Trial Phase	Trials
PHASE3	1
Phase 4	1
Phase 2	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for APRACLONIDINE HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	2
Unknown status	1
Not yet recruiting	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for APRACLONIDINE HYDROCHLORIDE

Sponsor Name

Chart
Table

Sponsor Name for APRACLONIDINE HYDROCHLORIDE
Sponsor	Trials
Alcon Research	1
Walter Reed Army Medical Center	1
American University of Beirut Medical Center	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for APRACLONIDINE HYDROCHLORIDE
Sponsor	Trials
Other	2
INDUSTRY	1
U.S. Fed	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.